[CAS NO. 3376-24-7] N-tert-Butyl-α-phenylnitrone
PRODUCTS SPECIFICATIONS [3376-24-7]
DESCRIPTION [3376-24-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 177.24 |
| Molecular Formula | C11H15NO |
| SMILES | CC(/[N+]([O-])=C/C1=CC=CC=C1)(C)C |
Summary
N-tert-Butyl-α-phenylnitrone is a nitrone-based free radical scavenger that forms nitroxide spin adducts. N-tert-Butyl-α-phenylnitrone inhibits COX2 catalytic activity. N-tert-Butyl-α-phenylnitrone has potent ROS scavenging, anti-inflammatory, neuroprotective, anti-aging and anti-diabetic activities, and can penetrate the blood-brain barrier [1] [2] [3] [4] .
IC50 & Target
|
COX-2 |
Reactive oxygen species (ROS) |
In Vitro
N-tert-Butyl-α-phenylnitrone (PBN) (25-100 µM) treatment leads to a significant decrease in 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH)-induced intracellular ROS accumulation. N-tert-Butyl-α-phenylnitrone also attenuates AAPH-induced cytotoxicity, matrix degradation, and apoptosis. N-tert-Butyl-α-phenylnitrone suppresses AAPH-induced activation of ERK/MAPK pathway. N-tert-Butyl-α-phenylnitrone has the potenial for intervertebral disc degeneration (IDD) research [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
N-tert-Butyl-α-phenylnitrone (PBN; 100 mg/kg; intraperitoneal injection; twice a day; C57Bl/6 mice) treatment not only abolishes the LPS-induced lipid peroxidation, nitrotyrosine residue levels, and GSH depletion, but also decreases the incidence of external malformations [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57Bl/6 mice induced by lipopolysaccharide (LPS) [2] |
| Dosage: | 100 mg/kg |
| Administration: | Intraperitoneal injection; twice a day (on gestational day 8) |
| Result: | Abolished LPS-induced lipid peroxidation, nitrotyrosine residues, and GSH depletion. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 564.21 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.6421 mL | 28.2103 mL | 56.4207 mL |
| 5 mM | 1.1284 mL | 5.6421 mL | 11.2841 mL |
| 10 mM | 0.5642 mL | 2.8210 mL | 5.6421 mL |
References
- [1] Zhenggang Zhou, et al. PBN Protects NP Cells From AAPH-induced Degenerative Changes by Inhibiting the ERK1/2 Pathway. Connect Tissue Res. 2020 Mar 30;1-10.
- [2] Lei Zhao, et al. Reactive Oxygen Species Contribute to Lipopolysaccharide-Induced Teratogenesis in Mice. Toxicol Sci. 2008 May;103(1):149-57.
- [3] Y Kotake, et al. Inhibition of NF-kappaB, iNOS mRNA, COX2 mRNA, and COX Catalytic Activity by phenyl-N-tert-butylnitrone (PBN). Biochim Biophys Acta. 1998 Nov 19;1448(1):77-84.
- [4] R A Floyd. Antioxidants, Oxidative Stress, and Degenerative Neurological Disorders. Proc Soc Exp Biol Med. 1999 Dec;222(3):236-45.
Synonyms